Consensus on resectability in N3 head and neck squamous cell carcinomas: GETTEC recommendations

Carsuzaa, Florent; Gorphe, Philippe; Vergez, S.; Malard, O.; Fakhry, Nicolas; Righini, Christian; Philouze, Pierre; Lasne-Cardon, Audrey; Gallet, P.; Tonnerre, Denis; Bozec, A.; Monès, Erwan de; Baujat, B.; Laccourreye, L.; Babin, E.; Dufour, Xavier; Thariat, Juliette

doi:10.1016/j.oraloncology.2020.104733

Cited by 6 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other small to medium-size studies have reported better PFS but not better survival [ 22 , 23 ]. Further to our observation, French GETTEC guidelines for resectability criteria have been published to better assess the arguments for ND and the impact of strategies using ND [ 24 ].…”

Section: Discussionmentioning

confidence: 89%

Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary

Abu-Shama

Salleron

Carsuzaa

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Purpose: Management of head and neck cancers of unknown primary (HNCUP) combines neck dissection (ND) and radiotherapy, with or without chemotherapy. The prognostic value of ND has hardly been studied in HNCUP. Methods: A retrospective multicentric study assessed the impact of ND extent (adenectomy, selective ND, radical/radical-modified ND) on nodal relapse, progression-free survival (PFS) or survival, taking into account nodal stage. Results: 53 patients (16.5%) had no ND, 33 (10.2%) had lymphadenectomy, 116 (36.0%) underwent selective ND and 120 underwent radical/radical-modified ND (37.3%), 15 of which received radical ND (4.7%). With a 34-month median follow-up, the 3-year incidence of nodal relapse was 12.5% and progression-free survival (PFS) 69.1%. In multivariate analysis after adjusting for nodal stage, the risk of nodal relapse or progression was reduced with lymphadenectomy, selective or radical/modified ND, but survival rates were similar. Patients undergoing lymphadenectomy or ND had a better PFS and lowered nodal relapse incidence in the N1 + N2a group, but the improvement was not significant for the N2b or N2 + N3c patients. Severe toxicity rates exceeded 40% with radical ND. Conclusion: In HNCUP, ND improves PFS, regardless of nodal stage. The magnitude of the benefit of ND does not appear to depend on ND extent and decreases with a more advanced nodal stage.

show abstract

Section: Discussionmentioning

confidence: 89%

Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary

Abu-Shama

Salleron

Carsuzaa

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Primary neck dissection when the primary tumour is to be treated with RT or chemoradiotherapy, even in cases of resectable N 3 disease, is not routinely recommended, but should be considered on a case-by-case basis. 1090,1091 One indication may be cases where there is skin ulceration and possible haemorrhage risk.…”

Section: Recommendationsmentioning

confidence: 99%

Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition

Homer,

Winter,

Abbey

et al. 2024

J. Laryngol. Otol.

View full text Add to dashboard Cite

“…Retropharyngeal lymph nodes are a common metastatic site for some head and neck cancers, and their involvement often leads to the disease being considered unresectable [ 77 ]. However, TORS has been used to treat retropharyngeal node metastasis instead of RT or as an adjunct, in order to reduce RT toxicity and to provide a reliable staging that could guide treatment [ 10 , 78 ].…”

Section: Tors Applications In Hncmentioning

confidence: 99%

Transoral Robotic Surgery for Head and Neck Cancer: Advances and Residual Knowledge Gaps

Mella

Chabrillac

Dupret‐Bories

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Minimally invasive surgery is a growing field in surgical oncology. After acquiring its first Food and Drug Administration approval in 2009 for T1–T2 malignancies of the oral cavity, oropharynx, and larynx, transoral robotic surgery (TORS) has gained popularity thanks to its wristed instruments and magnified three-dimensional view, enhancing surgical comfort in remote-access areas. Its indications are expanding in the treatment of head and neck cancer, i.e., resection of tumors of the larynx, hypopharynx, or parapharyngeal space. However, this expansion must remain cautious and based on high-level evidence, in order to guarantee safety and oncological outcomes which are comparable to conventional approaches. This narrative review assesses the current role of TORS in head and neck cancer from an evidence-based perspective, and then identifies what knowledge gaps remain to be addressed.

show abstract

Consensus on resectability in N3 head and neck squamous cell carcinomas: GETTEC recommendations

Cited by 6 publications

References 14 publications

Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary

Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary

Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition

Transoral Robotic Surgery for Head and Neck Cancer: Advances and Residual Knowledge Gaps

Contact Info

Product

Resources

About